12 July 2024 | HK | IS | Approval Alert: Eisai’s Leqembi® (Lecanemab) Approved in Hong Kong and Israel for Alzheimer's...

Home / News / Pearce IP Blog
12 July 2024 | HK | IS | Approval Alert: Eisai’s Leqembi® (Lecanemab) Approved in Hong Kong and Israel for Alzheimer's...
Elanco Australasia Pty Ltd v Abbey Laboratories Pty Ltd [2024] FCA 640
7 July 2024 | IN | Approval Alert: Zydus Life Sciences’ Biosimilar Nivolumab Approved in IndiaOn 7 July 2024, Medical...
28 June 2024 | Shanghai Henlius Biotech Completes Phase 1 Trials for Daratumumab Biosimilar Shanghai Henlius Biotech...
14 June 2024 | AU | Approval Alert: Bayer’s High Dose Eylea® (aflibercept) Approved in Australia On 14 June 2024,...
31 May 2024 | EU | US | Europe’s CHMP Recommends Dupixent® (Dupilumab) as COPD Add-On Treatment On 31 May 2024,...
SARB Management Group Pty Ltd trading as Database Consultants Australia v Vehicle Monitoring Systems Pty Limited (No 2) [2024] FCAFC 53
24 MAY 2024 | EU | Shanghai Henlius’ & Organon’s Biosimilar Denosumab Applications Validated by EMA On 24 May...
17 MAY 2024 | KR | New Indication Alert: MSD’s Keytruda® (Pembrolizumab) Approved in Korea for New NSCLC and Cervical...
R F Industries Pty Ltd v Mine Site Technologies Pty Ltd [2024] APO 16 provides a good example of the usefulness of re-examination and opposition to challenge a granted patent.
10 MAY 2024 | US | Valorum Biologics to Launch Xbrane and Stada’s Ranibizumab Biosimilar in the US On 10 May 2024,...
03 MAY 2024 | CA | Lupin & Sandoz Launch Rymti® (etanercept) Biosimilar in Canada On 3 May 2024,...
Vald Pty Ltd sued KangaTech Pty Ltd for patent infringement and Kanga cross-claimed alleging that Vald’s patent is invalid on the basis of lack of support, lack of sufficiency and lack of inventive step.
Justice Rofe has delivered a further supplementary decision in the dispute between Boehringer Ingelheim Animal Health USA Inc (Boehringer) and Zoetis Services LLC (Zoetis) in relation to three Zoetis vaccine patent applications. Her Honour has now held the last remaining valid claim to be invalid for failure to disclose the best method of performing the claimed invention.
29 APR 2024 | KR | Samil Pharmaceutical to Launch Samsung Bioepis’ Aflibercept in Korean Market from 1 May The Korean...
21 APR 2024 | US | Xbrane to Resubmit BLA for Ranibizumab Biosimilar following FDA CRL On 21 April 2024, Swedish...